entertainment -WSS

entertainment

author：entertainment 2025-10-04 04:00:00 - browse：53

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Did you have Obamacare on your GOP debate bingo card?

WSS

Listen: Who gets the credit for GLP

AI gets buy

A protest over insulin prices is seen as a fight for life

WHO recommends dropping component of many flu vaccines

Medicaid, Medicare dual

A protest over insulin prices is seen as a fight for life

focus

entertainment

hotspot

Apple is now the first public company to be valued at $3 trillion

Why CTE doesn’t keep Americans from enjoying the Super Bowl

After affirmative action ruling, medical educators look to 'holistic review'

FDA seeks to regulate lab

The high cost of giving birth even with insurance

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Cancer drug shortages should be causing more outrage

AstraZeneca stays mum on Medicare drug pricing negotiations

The high cost of giving birth even with insurance

Medicare drug price negotiation program allowed for now

entertainment

Surgery pushed Ben Carson to fame

Listen: Who gets the credit for GLP

After a drawn out lobbying fight, ARPA

Surgery pushed Ben Carson to fame

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Readout LOUD: Venture capital, Gilead, and more M&A

focus

leisure time

entertainment

focus